Daniela Caravelli
Overview
Explore the profile of Daniela Caravelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gurnari C, Koster L, Baaij L, Heiblig M, Yakoub-Agha I, Collin M, et al.
Blood Adv
. 2024 Feb;
8(6):1444-1448.
PMID: 38330178
No abstract available.
2.
Lupia T, Carnevale-Schianca F, Vita D, Busca A, Caravelli D, Crisa E, et al.
Medicina (Kaunas)
. 2024 Jan;
60(1).
PMID: 38256349
: is a ubiquitous, aerobic, Gram-negative bacillus causing increasing concern in patients affected by haematological malignancies. : We report a case series from two centres in Northern Italy to describe...
3.
Poletto S, Paruzzo L, Nepote A, Caravelli D, Sangiolo D, Carnevale-Schianca F
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201531
The introduction of immunotherapy revolutionized the treatment landscape in metastatic melanoma. Despite the impressive results associated with immune checkpoint inhibitors (ICIs), only a portion of patients obtain a response to...
4.
Gurnari C, Pascale M, Vitale A, Diral E, Tomelleri A, Galossi E, et al.
Am J Hematol
. 2023 Dec;
99(2):254-262.
PMID: 38108611
VEXAS is a prototypic hemato-inflammatory disease combining rheumatologic and hematologic disorders in a molecularly defined nosological entity. In this nationwide study, we aimed at screenshotting the current diagnostic capabilities and...
5.
Giraudo L, Cattaneo G, Gammaitoni L, Iaia I, Donini C, Massa A, et al.
J Exp Clin Cancer Res
. 2023 Nov;
42(1):310.
PMID: 37993874
Background: Even acknowledging the game-changing results achieved in the treatment of metastatic melanoma with the use of immune checkpoint inhibitors (ICI), a large proportion of patients (40-60%) still fail to...
6.
Lupia T, Crisa E, Gaviraghi A, Rizzello B, Di Vincenzo A, Carnevale-Schianca F, et al.
Trop Med Infect Dis
. 2023 Jul;
8(7).
PMID: 37505654
and cytomegalovirus co-infections are rarely reported, even though they are distinguished by high morbidity and mortality, especially in immunocompromised hosts. We narratively reviewed the literature on reported cases of and...
7.
Lupia T, Crisa E, Gaviraghi A, Rizzello B, Di Vincenzo A, Carnevale-Schianca F, et al.
Trop Med Infect Dis
. 2023 Jun;
8(6).
PMID: 37368749
To our knowledge, we have described the first case of /Cytomegalovirus (CMV) concomitant infection that occurred in a European country. The patient was a 76-year-old woman affected by relapsed non-Hodgkin...
8.
Carnevale-Schianca F, Caravelli D, Gallo S, Becco P, Paruzzo L, Poletto S, et al.
J Clin Med
. 2021 Apr;
10(6).
PMID: 33799685
Combined direct antineoplastic activity and the long-lasting immunological effects of allogeneic hematopoietic cell transplant (HCT) can cure many hematological malignancies, but broad adoption requires non-relapse mortality (NRM) rates and graft-versus-host...
9.
Becco P, Gallo S, Poletto S, Frascione M, Crotto L, Zaccagna A, et al.
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32575838
Malignant melanoma is the third most common type of tumor that causes brain metastases. Patients with cerebral involvement have a dismal prognosis and their treatment is an unmet medical need....
10.
Pastore D, Bruno B, Carluccio P, De Candia M, Mammoliti S, Borghero C, et al.
Ann Hematol
. 2020 Feb;
99(4):867-875.
PMID: 32036421
A survey within hematopoietic stem cell transplant (HSCT) centers of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) was performed in order to describe current antiemetic prophylaxis in patients undergoing HSCT....